Akebia Therapeutics, Inc.AKBANASDAQ
Loading
SG&A Expenses Over TimeStable
Percentile Rank69
3Y CAGR-7.9%
5Y CAGR-6.8%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
-7.9%/yr
vs +12.3%/yr prior
5Y CAGR
-6.8%/yr
Consistent
Acceleration
-20.2pp
Decelerating
Percentile
P69
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
2 yr
Consecutive growthStable
PeriodValueYoY Change
TTM$108.38M+1.7%
2024$106.55M+6.3%
2023$100.23M-27.7%
2022$138.60M-20.4%
2021$174.14M+13.0%
2020$154.10M+3.1%
2019$149.46M+71.7%
2018$87.06M+222.4%
2017$27.01M+21.6%
2016$22.21M-